The Getinge Group have reported a positive development after three quarters of the fiscal year. In all key financial ratios, the success of the Swedes after nine months can be seen: order intake increased by 14 percent to 17,767 billion (2011: 15,579 billion). Sales also grew by 13.3 percent to SEK 16,433 billion. The organic growth of the Swedish medicine manufacturer was 4.3 percent.
Getinge recorded pre-tax profit growth of 4.0 percent to SEK 1,989 million (2011: SEK 1,913 million). The bottom line shows that the Swedish company earned SEK 1,472 million in the first nine months of the current fiscal year (2011: SEK 1, 416 million, +4.0%).
The acquisition of the U.S. company’s Therapeutic Support Systems (TSS) has contributed to this sales growth: the U.S. company Kinetic Concepts Inc. (KCI) had outsourced its division to TSS midway through the year, so the Getinge Group may also assume control of this. Getinge, as one of the leading European companies in the field of pressure ulcer prevention and treatment, has strengthened its position by taking over the American market.
[ilink url=“http://www.getingegroup.com/en/Press/Press-releases-Active/Interim-report-January—September-2012/“] Link zur Quelle (Getinge)[/ilink]